Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NERO trial of niraparib versus active symptom control in previously treated mesothelioma
ISRCTN16171129Phase 2Completed
- Sponsor
- University Hospital Southampton NHS Foundation Trust
- Start
- Jul 2022
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of niraparib in mesothelioma (2 arms), sponsored by University Hospital Southampton NHS Foundation Trust. Primary endpoint: Progression-free survival. Started Jul 2022; status: completed.
02
Drugs
niraparib
03
Conditions
mesothelioma
Beyond the preview
Go deeper on ISRCTN16171129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN16171129.